Kairos Pharma, Ltd.
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to dep… Read more
Kairos Pharma, Ltd. (KAPA) - Total Assets
Latest total assets as of September 2025: $8.07 Million USD
Based on the latest financial reports, Kairos Pharma, Ltd. (KAPA) holds total assets worth $8.07 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Kairos Pharma, Ltd. - Total Assets Trend (2020–2024)
This chart illustrates how Kairos Pharma, Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Kairos Pharma, Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Kairos Pharma, Ltd.'s total assets of $8.07 Million consist of 67.1% current assets and 32.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $222.00K | 3.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Kairos Pharma, Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kairos Pharma, Ltd.'s current assets represent 67.1% of total assets in 2024, a decrease from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 20.5% of total assets in 2024, down from 100.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 3.6% of total assets.
Kairos Pharma, Ltd. Competitors by Total Assets
Key competitors of Kairos Pharma, Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Kairos Pharma, Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Kairos Pharma, Ltd. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Kairos Pharma, Ltd. is currently not profitable relative to its asset base.
Kairos Pharma, Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 16.56 | 2.84 | 0.27 |
| Quick Ratio | 16.56 | 2.84 | 0.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.25 Million | $ 3.07 Million | $ -1.20 Million |
Kairos Pharma, Ltd. - Advanced Valuation Insights
This section examines the relationship between Kairos Pharma, Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.62 |
| Latest Market Cap to Assets Ratio | 1.19 |
| Asset Growth Rate (YoY) | 544.1% |
| Total Assets | $6.22 Million |
| Market Capitalization | $7.38 Million USD |
Valuation Analysis
Above Book Valuation: The market values Kairos Pharma, Ltd.'s assets above their book value (1.19 x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Kairos Pharma, Ltd.'s assets grew by 544.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Kairos Pharma, Ltd. (2020–2024)
The table below shows the annual total assets of Kairos Pharma, Ltd. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $6.22 Million | +544.15% |
| 2023-12-31 | $965.00K | -6.85% |
| 2022-12-31 | $1.04 Million | +33.68% |
| 2021-12-31 | $775.00K | +5316.55% |
| 2020-12-31 | $14.31K | -- |